
Need
Chronic respiratory disease – a growing socio-economic burden
Asthma and chronic obstructive pulmonary disease (COPD) affect over half a billion people worldwide1,2 with the prevalence of both conditions increasing due to environmental, social and behavioural factors.1,3 While effective medications exist, non-adherence to prescribed dose is a major issue, leading to costly exacerbations and hospitalizations. Such is the scale of the problem, global guidelines now recommend monitoring adherence prior to any change in prescription.4
References:
1 WHO FactsheetCOPD 2017. www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
2 WHO Factsheet Asthma 2020. www.who.int/news-room/fact-sheets/detail/asthma
3 Nunes C et al. Asthma Res Pract 2017; 3:1. DOI 10.1186/s40733-016- 0029-3.
4 Global Initiative for Asthma. www.ginasthma.org
Economic impact of medication non-adherence in the US
26m
US patient population with asthma1
25m
Estimated US patient population with COPD2
~38%
children with asthma are uncontrolled3
~50%
adults with asthma are uncontrolled3
1.3m+
severe treated asthma & COPD patients4
11m+
asthmatics reported one or more exacerbations in 12 months5
3.5m+
ER visits asthma patients2 & COPD patients6
0.9m+
hospitalisations asthma patients2 & COPD patients6
$1,400
CPT RPM code physician billable per patient annually7
$433 - $1,500
cost per ER visit for asthma8,9 & COPD10
$5,040 - $9,815
cost per hospitalisation for astma11,12 & COPD10
Source:
1 Centre for Disease Control; httpd://www.cdc.gov/asthma/index.html
2 American Lung Association estimate based on: https://www.sciencedaily.com/releases/2014/07/140724112551.htm
3 https://www.cdc.gov/asthma/asthma_stats/uncontrolled_asthma.htm
4 Patient Epidemiology sources; GINA/GOLD/Global Asthma Network data 2017 (source AZ Investor presentation)
5 https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
6 ES Ford. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the Nationwide Inpatient Sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011 Chest, 147 (2015), pp. 989-998
7 CPT CODE 99453, 99454.99457
8 Pearson WS, Goates SA, Harrykissoon SD, Miller SA. State-based Medicaid costs for pediatric asthma emergency department visits. Prev Chronic Dis. 2014;11:E108
9 Wang T, Srebotnjak T, Brownwell J, Hsia RY. Emergency Department Charges for Asthma-related Outpatient Visits by Insurance Status. J Health Care Poor Underserved. 2014 February ; 25(1): 396–405
10 Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454–460
11 Hasegawa K, Tsugawa Y, Brown DF, Camargo CA Jr. Childhood asthma hospitalizations in the United States, 2000–2009. J Pediatr. 2013;163(4):1127.e3–1133.e3
Hailie® Solution - clinically proven to reduce acute attacks and hospitalisations
Adherium’s Hailie® digital solution comprises patented sensors and proprietary algorithms that track medication delivery, capturing data for clinicians and generating auditable reimbursement reports for payers and providers.
- Most clinical evidence of any digital respiratory monitor (>85 studies involving 13,000 patients)
- Clinically proven to improve adherence and outcomes
- >180,000 devices sold in 30 countries
- Widest US inhaler market coverage
- Funded technology upgrade will access US reimbursement
Proportion of asthmatics with difficult to treat / severe asthma
-
24%
GINA Step 4-5 treatment
-
17%
Difficult-to-treat asthma
GINA Step 4-5 treatment + poor symptom control
-
3.7%
Severe asthma
GINA Step 4-5 treatment + poor symptom control + good adherence & inhaler technique